1586. Phase 3/3b Experience with Long-Acting Cabotegravir and Rilpivirine: Efficacy and Safety Outcomes Through Week 96 by Race

BACKGROUND: Long-acting cabotegravir + rilpivirine (CAB + RPV LA) administered monthly or every 2 months is the first and only complete LA regimen recommended by treatment guidelines for the maintenance of HIV-1 virologic suppression. This post hoc analysis summarizes pooled outcomes for participant...

Descripción completa

Detalles Bibliográficos
Autores principales: Patel, Parul, Elliot, Emilie, D’Amico, Ronald, Garside, Louise, Smith, Conor, Roberts, Jeremy, Polli, Joseph W, Ramgopal, Moti, Kumar, Princy N, Osiyemi, Olayemi, Baugh, Bryan, van Wyk, Jean A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751827/
http://dx.doi.org/10.1093/ofid/ofac492.109

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751827/
http://dx.doi.org/10.1093/ofid/ofac492.109

Ejemplares similares